Pre-HCT mosaicism increases relapse risk and lowers survival in acute lymphoblastic leukemia patients post-unrelated HCT. Blood Adv 2021 Jan 12;5(1):66-70
Date
02/12/2021Pubmed ID
33570634Pubmed Central ID
PMC7805319DOI
10.1182/bloodadvances.2020003366Scopus ID
2-s2.0-85099204908 (requires institutional sign-in at Scopus site) 5 CitationsAbstract
Pre-HCT mosaicism is related to increased relapse risk and lower survival after unrelated HCT, independent of cytogenetics at diagnosis. Pre-HCT mosaicism could be a useful clinical tool to guide risk stratification in acute lymphoblastic leukemia patients.
Author List
Wang Y, Zhou W, Wang J, Karaesmen E, Tang H, McCarthy PL, Pasquini MC, Wang Y, McReynolds LJ, Katki HA, Machiela MJ, Yeager M, Pooler L, Sheng X, Haiman CA, Van Den Berg D, Spellman SR, Wang T, Kuxhausen M, Chanock SJ, Lee SJ, Clay-Gilmour AI, Hahn TE, Gadalla SM, Sucheston-Campbell LEAuthors
Marcelo C. Pasquini MD, MS Professor in the Medicine department at Medical College of WisconsinTao Wang PhD Associate Professor in the Institute for Health and Equity department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
HumansMosaicism
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recurrence
Transplantation, Homologous
